Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03922451 · ClinicalTrials.gov registry record
Pharmacokinetics of Antibiotics During Extracorporeal Membrane Oxygenation (ECMO) Support
A clinical trial, sponsored by Boston Children's Hospital.
- Terminated
- Registry status
- 4
- Enrollment target
NCT03922451: Clinical Trial study, sponsored by Boston Children's Hospital.
NCT03922451 is a clinical trial that was terminated before completion, run by Boston Children's Hospital. The registered enrollment target is 4 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03922451 was terminated before completion, sponsored by Boston Children's Hospital.
- TERMINATED
- Registry status
- 4 participants
- Enrollment target
Study Summary
This study will measure plasma concentrations of piperacillin-tazobactam and cefazolin in pediatric patients supported with extracorporeal membrane oxygenation (ECMO) aiming to better understand the pharmacokinetics of these medications in this in vivo setting.
Primary Outcome
Drug levels will be checked at baseline followed by additional measurements after the dose based on the dosing intervals but anticipated to be 30, 60, 120, 360, 480 minutes after the dose. Dosing regime will be q8-12 hourly pending end organ function (at the discretion of the treating team). The study will be continued for the duration of the Antibiotic therapy whilst on ECMO support and for one set of samples following decannulation.
Interventions
- DRUG Cefazolin
- DRUG piperacillin-tazobactam
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 4 participants |
| Start Date | 2019-08-27 |
| Est. Completion | 2022-02-28 |
Why NCT03922451 stopped before completion
NCT03922451 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 4 participants, a relatively small participant target.
The record links to 0 conditions, and to 2 interventions - of which Cefazolin is the first listed.
NCT03922451 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT03922451 about?
NCT03922451 is a clinical study titled "Pharmacokinetics of Antibiotics During Extracorporeal Membrane Oxygenation (ECMO) Support". This study will measure plasma concentrations of piperacillin-tazobactam and cefazolin in pediatric patients supported with extracorporeal membrane oxygenation (ECMO) aiming to better understand the pharmacokinetics of these medications in this in vivo setting.
What is the current status of trial NCT03922451?
This trial is currently terminated. The enrollment target is 4 participants. The study started on 2019-08-27. Estimated completion is 2022-02-28.
What interventions are being tested in trial NCT03922451?
The interventions under investigation include: Cefazolin (DRUG), piperacillin-tazobactam (DRUG).
Who is sponsoring clinical trial NCT03922451?
This trial is sponsored by Boston Children's Hospital, which has 462 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI